ZenBio Engages Cryoport to Support Distribution of its Human Cell-Based Products
Jul 14, 2015, 08:30 ET
LAKE FOREST, Calif., July 14, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Cryoport" or the "Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company's validated cryogenic logistics solution is supporting ZenBio Inc. ("ZenBio") in the distribution of its Human Platelet Lysate as well as its entire array of cell-based solutions for the discovery and development of regenerative therapies.
ZenBio, based in Research Triangle Park, NC, offers its research partners a unique "cells and services" model delivering robust cell-based solutions to accelerate the discovery and development of therapies to better the human condition. There are different human blood components, cell tissues, and other products that support varying clinical development programs. The current initiative includes Human Serum to replace Bovine-derived products. Cryoport is providing the validated cryogenic logistics to deliver to ZenBio customers worldwide.
Peter Pieraccini, President and Chief Executive Officer of ZenBio, commented, "Cryoport is helping us grow with its reliable solutions for the distribution of our products. They play a critical role in the successful distribution of our products and services, giving us "peace of mind" and certainty. Our team is able to focus on the development of new products for the marketplace when we are in the hands of a reliable distribution partner. Cryoport is a significant asset for our team to leverage in our distribution strategies worldwide."
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "ZenBio provides great products that support the clinical programs of a large number of companies. We are proud to support ZenBio with our best-in-class cryogenic logistics solutions enabling its team to focus on the development of new products. We are delighted to have the opportunity and privilege to be ZenBio's cryogenic logistics partner and to provide solutions for its current and future business strategies."
About ZenBio, Inc.
Founded in 1995, ZenBio, Inc. ("ZB") is the industry leader in robust cell-based solutions to accelerate the discovery and development of therapies to better the human condition. The ZB mission is to provide the highest quality cells, reagents and contract services to the global biomedical research, pharmaceutical and biotechnology communities within the study of human metabolic disease.
ZB pioneered tissue engineering with adult adipose-derived stem cells and is currently expanding its product offering to address a variety of developmental and onset metabolic diseases such as obesity.
ZenBio is a privately held biotechnology company, located in Research Triangle Park and has extensive worldwide distribution through a network of technically experienced partners. For more information about ZenBio, Inc., go to www.zen-bio.com
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Logo - http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
SOURCE Cryoport, Inc.